



Per recent data from Prime Therapeutics, Medical drug spending is the fastest-growing segment, representing 25% of total drug spending. As part of Blue Cross Blue Shield of North Carolina's (Blue Cross NC) commitment to providing the most effective and affordable care through a total drug management approach, medical drug opportunities have been identified to optimize spend and utilization in key therapeutic categories for our members. Strategies included are selected based on clinical efficacy and/or superiority as well as cost-effectiveness, and have been evaluated through Blue Cross NC's Pharmacy and Therapeutics (P&T) Committee, aiming to improve health outcomes for members.

This Medical Management Drug Guide identifies specialty drugs and the various approaches to manage medical expenses effectively. These include incorporating biosimilars, medical rebates, step therapy strategies, quantity limits, partnering with specialty-focused vendors, and providing low net cost savings. Employers can utilize the guide to understand the strategies better and access a comprehensive list of drugs covered under the medical benefit that utilize these approaches.

For more information, please contact your authorized Blue Cross NC representative.

Note:

The Medical Management Drug Guide is not all-inclusive and does not reflect every medication that can be covered on the medical benefit. Certain medical drugs that have coverage available without medical necessity review may not be listed here. This Guide is regularly updated and is subject to change based on new approvals and market/industry changes. New-to-market products and variations of those products will not be added to the Medical Management Drug Guide until they have been endorsed by Blue Cross NC's P&T Committee.

Updated June 2023

Therapeutic Category	Prior Authorization Policy Name	Drug Name	Step Therapy	Preferred	Quantity Limits	Site of Care	Pharmacy Benefit Coverage	Channel Mgmt	Medical Oncology Program	High Cost Therapy Review
Analgesics - Misc	Pegloticase (Krystexxa)	Krystexxa (pegloticase)	Y							Y
Analgesics - Misc	Buprenorphine Extended-Release (Sublocade)	Sublocade (buprenorphine extended-release)								
Analgesics - Viscosupplements	Intra Articular Hyaluronan Injections for Treatment of Osteoarthritis of the Knee	Durolane (sodium hyaluronate)	Y							
Analgesics - Viscosupplements	Intra Articular Hyaluronan Injections for Treatment of Osteoarthritis of the Knee	Euflexxa (1% sodium hyaluronate)	Y							
Analgesics - Viscosupplements	Intra Articular Hyaluronan Injections for Treatment of Osteoarthritis of the Knee	Gel-One (cross-linked hyaluronate)	Y							
Analgesics - Viscosupplements	Intra Articular Hyaluronan Injections for Treatment of Osteoarthritis of the Knee	Gelsyn-3 (sodium hyaluronate)	Y							
Analgesics - Viscosupplements	Intra Articular Hyaluronan Injections for Treatment of Osteoarthritis of the Knee	GenVisc 850 (sodium hyaluronate)	Y							
Analgesics - Viscosupplements	Intra Articular Hyaluronan Injections for Treatment of Osteoarthritis of the Knee	Hyalgan (sodium hyaluronate)	Y							
Analgesics - Viscosupplements	Intra Articular Hyaluronan Injections for Treatment of Osteoarthritis of the Knee	Hymovis (high molecular weight viscoelastic hyaluronan)	Y							
Analgesics - Viscosupplements	Intra Articular Hyaluronan Injections for Treatment of Osteoarthritis of the Knee	Monovisc (cross-linked high molecular weight hyaluronic acid)	Y							
Analgesics - Viscosupplements	Intra Articular Hyaluronan Injections for Treatment of Osteoarthritis of the Knee	Orthovisc (high molecular weight hyaluronan)	Y	Y						
Analgesics - Viscosupplements	Intra Articular Hyaluronan Injections for Treatment of Osteoarthritis of the Knee	Supartz (sodium hyaluronate)	Y							
Analgesics - Viscosupplements	Intra Articular Hyaluronan Injections for Treatment of Osteoarthritis of the Knee	Supartz FX (sodium hyaluronate)	Y							
Analgesics - Viscosupplements	Intra Articular Hyaluronan Injections for Treatment of Osteoarthritis of the Knee	Synojynt (1% sodium hyaluronate)	Y							
Analgesics - Viscosupplements	Intra Articular Hyaluronan Injections for Treatment of Osteoarthritis of the Knee	Synvisc (hylan G-F 20)	Y	Y						
Analgesics - Viscosupplements	Intra Articular Hyaluronan Injections for Treatment of Osteoarthritis of the Knee	Synvisc-One (hylan G-F 20)	Y	Y						
Analgesics - Viscosupplements	Intra Articular Hyaluronan Injections for Treatment of Osteoarthritis of the Knee	Triluron (sodium hyaluronate)	Y							
Analgesics - Viscosupplements	Intra Articular Hyaluronan Injections for Treatment of Osteoarthritis of the Knee	TriVisc (sodium hyaluronate)	Y							
Analgesics - Viscosupplements	Intra Articular Hyaluronan Injections for Treatment of Osteoarthritis of the Knee	Visco-3 (sodium hyaluronate)	Y							
Anti-Infective Agents	N/A	Apretude (cabotegravir)*								
Anti-Infective Agents	Ibalizumab-uiyk (Trogarzo)	Trogarzo (ibalizumab-uiyk)				Y				
Anti-Infective Agents	Letermovir (Prevymis)	Prevymis (letermovir)	Y			Y	Y			

Therapeutic Category	Prior Authorization Policy Name	Drug Name	Step Therapy	Preferred	Quantity Limits	Site of Care	Pharmacy Benefit Coverage	Channel Mgmt	Medical Oncology Program	High Cost Therapy Review
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Tivdak (tisotumab vedotin-tftv)							Y	
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Abraxane (paclitaxel (protein-bound))							Y	
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Adcetris (brentuximab vedotin)							Y	
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Alimta (pemetrexed)							Y	
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Aliqopa (copanlisib)							Y	
Antineoplastic Agents	Preferred Injectable Oncology Program	Alymsys (bevacizumab-maly)	Y							
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Arzerra (ofatumumab)							Y	
Antineoplastic Agents	Preferred Injectable Oncology Program	Avastin (bevacizumab)	Y							
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Bavencio (avelumab)							Y	
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Besponsa (inotuzumab ozogamicin)							Y	
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Blenrep (belantamab mafodotin-blmf)							Y	
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Blinicyto (blinatumomab)							Y	
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Danyelza (naxitamab-gqgk)							Y	
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Darzalex Faspro (daratumumab and hyaluronidase-fihj)							Y	
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Darzalex (daratumumab)							Y	
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Elahere (mirvetuximab soravtansine-gynx)							Y	
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Elzonris (tagraxofusp-erzs)							Y	
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Empliciti (elotuzumab)							Y	
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Enhertu (fam-trastuzumab deruxtecan-nxki)							Y	
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Erbix (cetuximab)							Y	
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Erwinaze (asparaginase <i>Erwinia chrysanthemi</i>)							Y	
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Fyarro (sirolimus albumin-bound nanoparticles)							Y	

Therapeutic Category	Prior Authorization Policy Name	Drug Name	Step Therapy	Preferred	Quantity Limits	Site of Care	Pharmacy Benefit Coverage	Channel Mgmt	Medical Oncology Program	High Cost Therapy Review
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Gazyva (obinutuzumab)							Y	
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Halaven (eribulin mesylate)							Y	
Antineoplastic Agents	Preferred Injectable Oncology Program	Herceptin (trastuzumab)	Y							
Antineoplastic Agents	Preferred Injectable Oncology Program	Herceptin Hylecta (trastuzumab and hyaluronidase-oysk)	Y							
Antineoplastic Agents	Preferred Injectable Oncology Program	Herzuma (trastuzumab-pkrb)	Y							
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Hycamtin (topotecan)							Y	
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Imfinzi (durvalumab)							Y	
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Imjudo (tremelimumab-actl)							Y	
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Imlygic (talimogene laherparepvec)							Y	
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Jemperli (dostarlimab-gxly)							Y	
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Jevtana (cabazitaxel)							Y	
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Kadcyla (ado-trastuzumab emtansine)							Y	
Antineoplastic Agents	Preferred Injectable Oncology Program	Kanjinti (trastuzumab-anns)*		Y						
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Keytruda (pembrolizumab)							Y	
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Kimmtrak (tebentafusp-tebn)							Y	
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Kyprolis (carfilzomib)							Y	
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Libtayo (cemiplimab-rwlc)							Y	
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Lumoxiti (moxetumomab pasudotox-tdfk)							Y	
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Lunsumio (mosunetuzumab-axgb)							Y	
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Margenza (margetuximab-cmkb)							Y	
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Monjuvi (tafasitamab-cxix)							Y	
Antineoplastic Agents	Preferred Injectable Oncology Program	Mvasi (bevacizumab-awwb)*		Y						

Therapeutic Category	Prior Authorization Policy Name	Drug Name	Step Therapy	Preferred	Quantity Limits	Site of Care	Pharmacy Benefit Coverage	Channel Mgmt	Medical Oncology Program	High Cost Therapy Review
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Mylotarg (gemtuzumab ozogamicin)							Y	
Antineoplastic Agents	Preferred Injectable Oncology Program	Ogivri (trastuzumab-dkst)*		Y						
Antineoplastic Agents	Preferred Injectable Oncology Program	Ontruzant (trastuzumab-dttb)	Y							
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Opdivo (nivolumab)							Y	
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Opdualag (nivolumab and relatlimab-rmbw)							Y	
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Padcev (enfortumab vedotin-ejfv)							Y	
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Perjeta (pertuzumab)							Y	
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf)							Y	
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Polivy (polatuzumab vedotin-piiq)							Y	
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Portrazza (necitumumab)							Y	
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Poteligeo (mogamulizumab-kpkc)							Y	
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Provenge (sipuleucel-T)							Y	
Antineoplastic Agents	Preferred Injectable Oncology Program	Riabni (rituximab-arrx)	Y							
Antineoplastic Agents	Preferred Injectable Oncology Program	Rituxan (rituximab)	Y							
Antineoplastic Agents	Preferred Injectable Oncology Program	Rituxan Hycela (rituximab and hyaluronidase)	Y							
Antineoplastic Agents	Preferred Injectable Oncology Program	Ruxience (rituximab-pvvr)*		Y						
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Rybrevant (amivantamab-vmjw)							Y	
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Rylaze (asparaginase <i>Erwinia chrysanthemi</i> (recombinant)-rywn)							Y	
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Sarclisa (isatuximab-irfc)							Y	
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Sylvant (siltuximab)							Y	
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Tecentriq (atezolizumab)							Y	
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Tecvayli (teclistamab-cqyv)							Y	

Therapeutic Category	Prior Authorization Policy Name	Drug Name	Step Therapy	Preferred	Quantity Limits	Site of Care	Pharmacy Benefit Coverage	Channel Mgmt	Medical Oncology Program	High Cost Therapy Review
Antineoplastic Agents	Preferred Injectable Oncology Program	Trazimera (trastuzumab-qyyp)	Y							
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Trodelvy (sacituzumab govitecan-hziy)							Y	
Antineoplastic Agents	Preferred Injectable Oncology Program	Truxima (rituximab-abbs)*		Y						
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Vectibix (panitumumab)							Y	
Antineoplastic Agents	Preferred Injectable Oncology Program	Vegzelma (bevacizumab-adcd)	Y							
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Vyxeos (daunorubicin and cytarabine)							Y	
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Yervoy (ipilimumab)							Y	
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Zepzelca (lurbinectedin)							Y	
Antineoplastic Agents	Preferred Injectable Oncology Program	Zirabev (bevacizumab-bvzr)*		Y						
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Zoladex (goserelin)							Y	
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Zynlonta (loncastuximab tesirine-lpyl)							Y	
Antineoplastic Agents	Injectable and Healthcare Administered Oncology Drugs	Zynyz (retifanlimab-dlwr)							Y	
Autoimmune Agents - Anti-inflammatory Agents	Tocilizumab (Actemra)	Actemra (tocilizumab)	Y		Y	Y	Y			
Autoimmune Agents - Anti-inflammatory Agents	Infliximab (Remicade) and Infliximab Biosimilars	Avsola (infliximab-axxq)	Y	Y	Y	Y				
Autoimmune Agents - Anti-inflammatory Agents	Belimumab (Benlysta)	Benlysta (belimumab)				Y	Y	Y		
Autoimmune Agents - Anti-inflammatory Agents	Certolizumab pegol (Cimzia)	Cimzia (certolizumab pegol)	Y			Y	Y			
Autoimmune Agents - Anti-inflammatory Agents	Emapalumab-lzsg (Gamifant)	Gamifant (emapalumab-lzsg)								Y
Autoimmune Agents - Anti-inflammatory Agents	Canakinumab (Ilaris)	Ilaris (canakinumab)	Y			Y				
Autoimmune Agents - Anti-inflammatory Agents	Tildrakizumab-asmn (Ilumya)	Ilumya (tildrakizumab-asmn)	Y			Y				
Autoimmune Agents - Anti-inflammatory Agents	Infliximab (Remicade) and Infliximab Biosimilars	Inflectra (infliximab-dyyb)	Y	Y	Y	Y				
Autoimmune Agents - Anti-inflammatory Agents	Infliximab (Remicade) and Infliximab Biosimilars	Infliximab	Y		Y	Y				
Autoimmune Agents - Anti-inflammatory Agents	Abatacept (Orencia)	Orencia (abatacept)	Y		Y	Y	Y			

Therapeutic Category	Prior Authorization Policy Name	Drug Name	Step Therapy	Preferred	Quantity Limits	Site of Care	Pharmacy Benefit Coverage	Channel Mgmt	Medical Oncology Program	High Cost Therapy Review
Autoimmune Agents - Anti-inflammatory Agents	Infliximab (Remicade) and Infliximab Biosimilars	Remicade (infliximab)	Y		Y	Y				
Autoimmune Agents - Anti-inflammatory Agents	Infliximab (Remicade) and Infliximab Biosimilars	Renflexis (infliximab-abda)	Y		Y	Y				
Autoimmune Agents - Anti-inflammatory Agents	Rituximab for the Treatment of Rheumatoid Arthritis	Riabni (rituximab-arrx)	Y							
Autoimmune Agents - Anti-inflammatory Agents	Rituximab for the Treatment of Rheumatoid Arthritis	Rituxan (rituximab)	Y							
Autoimmune Agents - Anti-inflammatory Agents	Rituximab for the Treatment of Rheumatoid Arthritis	Ruxience (rituximab-pvvr)	Y	Y						
Autoimmune Agents - Anti-inflammatory Agents	Anifrolumab-fnia (Saphnelo)	Saphnelo (anifrolumab-fnia)				Y				
Autoimmune Agents - Anti-inflammatory Agents	Golimumab (Simponi Aria)	Simponi Aria (golimumab)	Y			Y	Y			
Autoimmune Agents - Anti-inflammatory Agents	Risankizumab-rzaa (Skyrizi)	Skyrizi (risankizumab-rzaa) intravenous	Y							
Autoimmune Agents - Anti-inflammatory Agents	Spesolimab-sbzo (Spevigo)	Spevigo (spesolimab-sbzo)								
Autoimmune Agents - Anti-inflammatory Agents	Ustekinumab (Stelara)	Stelara (ustekinumab)	Y		Y	Y	Y			
Autoimmune Agents - Anti-inflammatory Agents	Teprotumumab-trbw (Tepezza)	Tepezza (teprotumumab-trbw)	Y			Y				Y
Autoimmune Agents - Anti-inflammatory Agents	Guselkumab (Tremfya)	Tremfya (guselkumab)	Y			Y	Y			
Autoimmune Agents - Anti-inflammatory Agents	Rituximab for the Treatment of Rheumatoid Arthritis	Truxima (rituximab-abbs)	Y	Y						
Autoimmune Agents - Immune globulins	Immunoglobulin Therapy	Asceniv (immune globulin)				Y				
Autoimmune Agents - Immune globulins	Immunoglobulin Therapy	Bivigam (immune globulin)				Y				
Autoimmune Agents - Immune globulins	Immunoglobulin Therapy	Carimune NF (immune globulin)	Y			Y				
Autoimmune Agents - Immune globulins	Immunoglobulin Therapy	Cutaquig (immune globulin)				Y				
Autoimmune Agents - Immune globulins	Immunoglobulin Therapy	Cuvitru (immune globulin)				Y				
Autoimmune Agents - Immune globulins	Immunoglobulin Therapy	Flebogamma (immune globulin)	Y			Y				
Autoimmune Agents - Immune globulins	Immunoglobulin Therapy	Gammagard Liquid (immune globulin) (IV & SC)		Y		Y				
Autoimmune Agents - Immune globulins	Immunoglobulin Therapy	Gammagard S/D (immune globulin)	Y			Y				
Autoimmune Agents - Immune globulins	Immunoglobulin Therapy	Gammaked (immune globulin) (IV & SC)	Y	Y		Y				

Therapeutic Category	Prior Authorization Policy Name	Drug Name	Step Therapy	Preferred	Quantity Limits	Site of Care	Pharmacy Benefit Coverage	Channel Mgmt	Medical Oncology Program	High Cost Therapy Review
Autoimmune Agents - Immune globulins	Immunoglobulin Therapy	Gammaplex (immune globulin)	Y			Y				
Autoimmune Agents - Immune globulins	Immunoglobulin Therapy	Gamunex-C (immune globulin) (IV & SC)	Y	Y		Y				
Autoimmune Agents - Immune globulins	Immunoglobulin Therapy	Hizentra (immune globulin)		Y		Y				
Autoimmune Agents - Immune globulins	Immunoglobulin Therapy	Hyqvia (immune globulin/hyaluronidase)				Y				
Autoimmune Agents - Immune globulins	Immunoglobulin Therapy	Octagam (immune globulin)	Y	Y		Y				
Autoimmune Agents - Immune globulins	Immunoglobulin Therapy	Panzyga (immune globulin)	Y			Y				
Autoimmune Agents - Immune globulins	Immunoglobulin Therapy	Privigen (immune globulin)	Y	Y		Y				
Autoimmune Agents - Immune Globulins	Immunoglobulin Therapy	Xembify (immune globulin)		Y		Y				
Cardiovascular Agents - Antihyperlipidemic Agents	Evinacumab-dgnb (Evkeeza)	Evkeeza (evinacumab-dgnb)	Y			Y				
Cardiovascular Agents - Antihyperlipidemic Agents	Inclisiran (Leqvio)	Leqvio (inclisiran)	Y			Y				
Cardiovascular Agents - Pulmonary Hypertension Agents	Pulmonary Hypertension, Drug Management	Flolan (epoprostenol sodium)								
Cardiovascular Agents - Pulmonary Hypertension Agents	Pulmonary Hypertension, Drug Management	Remodulin (treprostinil sodium)	Y							
Cardiovascular Agents - Pulmonary Hypertension Agents	Pulmonary Hypertension, Drug Management	Tyvaso (treprostinil)					Y			
Cardiovascular Agents - Pulmonary Hypertension Agents	Pulmonary Hypertension, Drug Management	Veletri (epoprostenol)								
Cardiovascular Agents - Pulmonary Hypertension Agents	Pulmonary Hypertension, Drug Management	Ventavis (iloprost)					Y			
Central Nervous System Medications - Antimigraine Agents	Eptinezumab-jjmr (Vyepsti)	Vyepsti (eptinezumab-jjmr)	Y			Y				
Central Nervous System Medications - Antidepressants	Esketamine (Spravato) Nasal Spray	Spravato (esketamine)	Y				Y			
Central Nervous System Medications - Antidepressants	Brexanolone (Zulresso)	Zulresso (brexanolone)								
Central Nervous System Medications - Neurological Agents	Aducanumab-avwa (Aduhelm)	Aduhelm (aducanumab-avwa)								
Central Nervous System Medications - Neurological Agents	Lecanemab-irmb (Leqembi)	Leqembi (lecanemab-irmb)^								
Central Nervous System Medications - Neuromuscular Agents	Ublituximab-xiiy (Briumvi)	Briumvi (ublituximab-xiiy)	Y			Y				
Central Nervous System Medications - Neuromuscular Agents	Alemtuzumab (Lemtrada)	Lemtrada (alemtuzumab)	Y							

Therapeutic Category	Prior Authorization Policy Name	Drug Name	Step Therapy	Preferred	Quantity Limits	Site of Care	Pharmacy Benefit Coverage	Channel Mgmt	Medical Oncology Program	High Cost Therapy Review
Central Nervous System Medications - Neuromuscular Agents	Ocrelizumab (Ocrevus)	Ocrevus (ocrelizumab)	Y			Y				
Central Nervous System Medications - Neuromuscular Agents	Nusinersen (Spinraza)	Spinraza (nusinersen)								Y
Central Nervous System Medications - Neuromuscular Agents	Natalizumab (Tysabri)	Tysabri (natalizumab)	Y			Y				
Central Nervous System Medications - Neuromuscular Agents	Inebilizumab-cdon (Uplizna)	Uplizna (inebilizumab-cdon)	Y			Y				Y
Endocrine and Metabolic Agents - Antidiabetic Agents	Teplizumab-mzwv (Tzield)	Tzield (teplizumab-mzwv)								
Endocrine and Metabolic Agents - Enzyme Replacement Therapy	Enzyme Replacement Therapy (ERT) for Lysosomal Storage Disorders	Aldurazyme (laronidase)				Y				Y
Endocrine and Metabolic Agents - Enzyme Replacement Therapy	Enzyme Replacement Therapy (ERT) for Lysosomal Storage Disorders	Brineura (cerliponase alfa)								Y
Endocrine and Metabolic Agents - Enzyme Replacement Therapy	Enzyme Replacement Therapy (ERT) for Lysosomal Storage Disorders	Cerezyme (imiglucerase)				Y				Y
Endocrine and Metabolic Agents - Enzyme Replacement Therapy	Enzyme Replacement Therapy (ERT) for Lysosomal Storage Disorders	Elaprase (idursulfase)				Y				Y
Endocrine and Metabolic Agents - Enzyme Replacement Therapy	Enzyme Replacement Therapy (ERT) for Lysosomal Storage Disorders	Ellelyso (taliglucerase alfa)				Y				Y
Endocrine and Metabolic Agents - Enzyme Replacement Therapy	Enzyme Replacement Therapy (ERT) for Lysosomal Storage Disorders	Fabrazyme (agalsidase beta)				Y				Y
Endocrine and Metabolic Agents - Enzyme Replacement Therapy	Enzyme Replacement Therapy (ERT) for Lysosomal Storage Disorders	Kanuma (sebelipase alfa)				Y				Y
Endocrine and Metabolic Agents - Enzyme Replacement Therapy	Enzyme Replacement Therapy (ERT) for Lysosomal Storage Disorders	Lamzede (velmanase alfa-tycv)				Y				Y
Endocrine and Metabolic Agents - Enzyme Replacement Therapy	Enzyme Replacement Therapy (ERT) for Lysosomal Storage Disorders	Lumizyme (alglucosidase alfa)				Y				Y
Endocrine and Metabolic Agents - Enzyme Replacement Therapy	Enzyme Replacement Therapy (ERT) for Lysosomal Storage Disorders	Mepsevii (vestronidase alfa-vjbk)				Y				Y
Endocrine and Metabolic Agents - Enzyme Replacement Therapy	Enzyme Replacement Therapy (ERT) for Lysosomal Storage Disorders	Naglazyme (galsulfase)				Y				Y
Endocrine and Metabolic Agents - Enzyme Replacement Therapy	Enzyme Replacement Therapy (ERT) for Lysosomal Storage Disorders	Nexviazyme (avalglucosidase alfa-ngpt)				Y				Y
Endocrine and Metabolic Agents - Enzyme Replacement Therapy	Fosdenopterin (Nulibry)	Nulibry (fosdenopterin)				Y				Y
Endocrine and Metabolic Agents - Enzyme Replacement Therapy	Enzyme Replacement Therapy (ERT) for Lysosomal Storage Disorders	Vimizim (elosulfase alfa)				Y				Y
Endocrine and Metabolic Agents - Enzyme Replacement Therapy	Enzyme Replacement Therapy (ERT) for Lysosomal Storage Disorders	Vpriv (velaglucerase alfa)				Y				Y
Endocrine and Metabolic Agents - Enzyme Replacement Therapy	Enzyme Replacement Therapy (ERT) for Lysosomal Storage Disorders	Xenpozyme (olipudase alfa-rpcp)				Y				Y
Endocrine and Metabolic Agents - Hormonal Agents	Repository Corticotropin (Acthar Gel)	Acthar Gel (repository corticotropin)	Y				Y			

Therapeutic Category	Prior Authorization Policy Name	Drug Name	Step Therapy	Preferred	Quantity Limits	Site of Care	Pharmacy Benefit Coverage	Channel Mgmt	Medical Oncology Program	High Cost Therapy Review
Endocrine and Metabolic Agents - Hormonal Agents	Somatostatin Analogs	Sandostatin (octreotide)				Y	Y			
Endocrine and Metabolic Agents - Hormonal Agents	Somatostatin Analogs	Sandostatin LAR Depot (octreotide acetate)		Y		Y				
Endocrine and Metabolic Agents - Hormonal Agents	Somatostatin Analogs	Signifor LAR (pasireotide)	Y			Y	Y			
Endocrine and Metabolic Agents - Hormonal Agents	Somatostatin Analogs	Somatuline Depot (lanreotide)	Y			Y				
Endocrine and Metabolic Agents - Hormonal Agents	Testosterone Pellet Implantation for Androgen Deficiency	Testopel (testosterone) pellet								
Endocrine and Metabolic Agents - Misc	Romosozumab-aqqg (Evenity)	Evenity (romosozumab-aqqg)	Y			Y				
Endocrine and Metabolic Agents - Misc	Lumasiran (Oxlumo)	Oxlumo (lumasiran)				Y				Y
Endocrine and Metabolic Agents - Misc	Denosumab (Prolia, Xgeva)	Prolia (denosumab)	Y						Y	
Endocrine and Metabolic Agents - Misc	Denosumab (Prolia, Xgeva)	Xgeva (denosumab)	Y						Y	
Endocrine and Metabolic Agents - Misc	Burosumab-twza (Crysvita)	Crysvita (burosumab-twza)				Y				Y
Gastrointestinal Agents - Antiemetic Agents	Antiemetic Injection Therapy	Akynzeo (fosnetupitant/palonosetron)	Y				Y		Y	
Gastrointestinal Agents - Antiemetic Agents	Antiemetic Injection Therapy	Aloxi (palonosetron HCl)	Y						Y	
Gastrointestinal Agents - Antiemetic Agents	Antiemetic Injection Therapy	Cinvanti (aprepitant)	Y						Y	
Gastrointestinal Agents - Antiemetic Agents	Antiemetic Injection Therapy	Emend (fosaprepitant)	Y						Y	
Gastrointestinal Agents - Antiemetic Agents	Antiemetic Injection Therapy	Sustol (granisetron)	Y						Y	
Gastrointestinal Agents - Anti-inflammatory Agents	Vedolizumab (Entyvio)	Entyvio (vedolizumab)	Y		Y	Y				
Gastrointestinal Agents - Misc	Fecal Microbiota, Live - jsIm (Rebyota)	Rebyota (fecal microbiota, live - jsIm)								
Gastrointestinal Agents - Misc	Bezlotoxumab (Zinplava)	Zinplava (bezlotoxumab)								
Gene/Cellular Therapy	CAR-T Therapy	Abecma (idecabtagene vicleucel)								Y
Gene/Cellular Therapy	Nadofaragene firadenovec-vncg (Adstiladrin)	Adstiladrin (nadofaragene firadenovec-vncg)								Y
Gene/Cellular Therapy	CAR-T Therapy	Breyanzi (lisocabtagene maraleucel)								Y
Gene/Cellular Therapy	CAR-T Therapy	Carvykti (ciltacabtagene autoleucel)								Y

Therapeutic Category	Prior Authorization Policy Name	Drug Name	Step Therapy	Preferred	Quantity Limits	Site of Care	Pharmacy Benefit Coverage	Channel Mgmt	Medical Oncology Program	High Cost Therapy Review
Gene/Cellular Therapy	Etranacogene dezaparvovec-drlb (Hemgenix)	Hemgenix (etranacogene dezaparvovec-drlb)						Y		Y
Gene/Cellular Therapy	CAR-T Therapy	Kymriah (tisagenlecleucel)								Y
Gene/Cellular Therapy	Voretigene Neparvovec-rzyl (Luxturna)	Luxturna (voretigene neparvovec-rzyl)						Y		Y
Gene/Cellular Therapy	Allogeneic Processed Thymus Tissue-agdc (Rethymic)	Rethymic (allogeneic processed thymus tissue-agdc)								Y
Gene/Cellular Therapy	Elivaldogene autotemcel (Skysona)	Skysona (elivaldogene autotemcel)								Y
Gene/Cellular Therapy	CAR-T Therapy	Tecartus (brexucabtagene autoleucel)								Y
Gene/Cellular Therapy	CAR-T Therapy	Yescarta (axicabtagene ciloleucel)								Y
Gene/Cellular Therapy	Onasemnogene abeparvovec (Zolgensma)	Zolgensma (onasemnogene abeparvovec-xioi)						Y		Y
Gene/Cellular Therapy	Betibeglogene autotemcel (Zynteglo)	Zynteglo (betibeglogene autotemcel)						Y		Y
Genitourinary Agents - Misc	Injectable Clostridial Collagenase for Fibroproliferative Disorders	Xiaflex (collagenase clostridium histolyticum)								
Hematological Agents - Hematopoietic Agents	Erythropoiesis-Stimulating Agents (ESAs)	Aranesp (darbepoetin alfa)					Y		Y	
Hematological Agents - Hematopoietic Agents	Trilaciclib (Cosela)	Cosela (trilaciclib)							Y	
Hematological Agents - Hematopoietic Agents	Erythropoiesis-Stimulating Agents (ESAs)	Epogen (epoetin alfa)	Y				Y		Y	
Hematological Agents - Hematopoietic Agents	White Blood Cell Growth Factors	Fulphila (pegfilgrastim-jmdb)	Y				Y			
Hematological Agents - Hematopoietic Agents	White Blood Cell Growth Factors	Fylnetra (pegfilgrastim-pbbk)	Y				Y			
Hematological Agents - Hematopoietic Agents	White Blood Cell Growth Factors	Granix (tbo-filgrastim)	Y				Y			
Hematological Agents - Hematopoietic Agents	White Blood Cell Growth Factors	Leukine (sargramostim)					Y			
Hematological Agents - Hematopoietic Agents	Erythropoiesis-Stimulating Agents (ESAs)	Mircera (methoxy polyethylene glycol (PEG) epoetin-beta)					Y		Y	
Hematological Agents - Hematopoietic Agents	White Blood Cell Growth Factors	Neulasta (pegfilgrastim)	Y				Y			
Hematological Agents - Hematopoietic Agents	White Blood Cell Growth Factors	Neulasta OnPro (pegfilgrastim)	Y				Y	Y		
Hematological Agents - Hematopoietic Agents	White Blood Cell Growth Factors	Neupogen (filgrastim)	Y				Y			
Hematological Agents - Hematopoietic Agents	White Blood Cell Growth Factors	Nivestym (filgrastim-aafi)*		Y			Y			

Therapeutic Category	Prior Authorization Policy Name	Drug Name	Step Therapy	Preferred	Quantity Limits	Site of Care	Pharmacy Benefit Coverage	Channel Mgmt	Medical Oncology Program	High Cost Therapy Review
Hematological Agents - Hematopoietic Agents	Romiplostim (NPlate)	NPlate (romiplostim)	Y			Y				
Hematological Agents - Hematopoietic Agents	White Blood Cell Growth Factors	Nyvepria (pegfilgrastim-apgf)	Y				Y			
Hematological Agents - Hematopoietic Agents	Erythropoiesis-Stimulating Agents (ESAs)	Procrit (epoetin alfa)	Y				Y		Y	
Hematological Agents - Hematopoietic Agents	Luspatercept-aamt (Reblozyl)	Reblozyl (luspatercept-aamt)				Y				Y
Hematological Agents - Hematopoietic Agents	White Blood Cell Growth Factors	Releuko (filgrastim-ayow)	Y				Y			
Hematological Agents - Hematopoietic Agents	Erythropoiesis-Stimulating Agents (ESAs)	Retacrit (epoetin alfa-epbx)		Y			Y		Y	
Hematological Agents - Hematopoietic Agents	White Blood Cell Growth Factors	Rolvedon (eflapegrastrim-xnst)	Y							
Hematological Agents - Hematopoietic Agents	White Blood Cell Growth Factors	Stimufend (pegfilgrastim-fpgk)	Y				Y			
Hematological Agents - Hematopoietic Agents	White Blood Cell Growth Factors	Udenyca (pegfilgrastim-cbqv)*		Y			Y			
Hematological Agents - Hematopoietic Agents	White Blood Cell Growth Factors	Zarxio (filgrastim-sndz)*		Y			Y			
Hematological Agents - Hematopoietic Agents	White Blood Cell Growth Factors	Ziextenzo (pegfilgrastim-bmez)*		Y			Y			
Hematological Agents - Iron Replacement Therapy	Intravenous Iron Replacement Therapy	Injectafer (ferric carboxymaltose)	Y							
Hematological Agents - Iron Replacement Therapy	Intravenous Iron Replacement Therapy	Monoferric (ferric derisomaltose)	Y							
Hematological Agents - Misc	Crizanlizumab-tmca (Adakveo)	Adakveo (crizanlizumab-tmca)	Y			Y				Y
Hematological Agents - Misc	Treatment of Hereditary Angioedema	Berinert (C1 esterase inhibitor)				Y	Y			
Hematological Agents - Misc	Treatment of Hereditary Angioedema	Cinryze (C1 esterase inhibitor)				Y				
Hematological Agents - Misc	Pegcetacoplan (Empaveli)	Empaveli (pegcetacoplan)				Y	Y			Y
Hematological Agents - Misc	Sutimlimab (Enjaymo)	Enjaymo (sutimlimab-jome)	Y			Y				Y
Hematological Agents - Misc	Treatment of Hereditary Angioedema	Firazyr (icatibant)				Y	Y			
Hematological Agents - Misc	Givosiran (Givlaari)	Givlaari (givosiran)				Y				Y
Hematological Agents - Misc	Treatment of Hereditary Angioedema	Kalbitor (ecallantide)				Y				
Hematological Agents - Misc	Treatment of Hereditary Angioedema	Ruconest (C1 esterase inhibitor)				Y	Y			

Therapeutic Category	Prior Authorization Policy Name	Drug Name	Step Therapy	Preferred	Quantity Limits	Site of Care	Pharmacy Benefit Coverage	Channel Mgmt	Medical Oncology Program	High Cost Therapy Review
Hematological Agents - Misc	Plasminogen, human-tvmh (Ryplazim)	Ryplazim (plasminogen, human-tvmh)				Y				Y
Hematological Agents - Misc	Eculizumab (Soliris)	Soliris (eculizumab)	Y			Y				Y
Hematological Agents - Misc	Ravulizumab-cwvz (Ultomiris)	Ultomiris (ravulizumab-cwvz)	Y			Y				Y
Neuromuscular Agents - Botulinum Toxins	Botulinum Toxin Injection	Botox (onabotulinumtoxinA)	Y							
Neuromuscular Agents - Botulinum Toxins	Botulinum Toxin Injection	Daxxify (daxibotulinumtoxinA-lanm)								
Neuromuscular Agents - Botulinum Toxins	Botulinum Toxin Injection	Dysport (abobotulinumtoxinA)		Y						
Neuromuscular Agents - Botulinum Toxins	Botulinum Toxin Injection	Myobloc (rimabotulinumtoxinB)	Y							
Neuromuscular Agents - Botulinum Toxins	Botulinum Toxin Injection	Xeomin (incobotulinumtoxinA)	Y	Y						
Neuromuscular Agents - Misc	Antisense Oligonucleotide Therapy for Duchenne Muscular Dystrophy	Amondys 45 (casimersen)^								
Neuromuscular Agents - Misc	Vutrisiran (Amvuttra)	Amvuttra (vutrisiran)				Y				Y
Neuromuscular Agents - Misc	Antisense Oligonucleotide Therapy for Duchenne Muscular Dystrophy	Exondys 51 (eteplirsen)^								
Neuromuscular Agents - Misc	Patisiran (Onpattro)	Onpattro (patisiran)				Y				Y
Neuromuscular Agents - Misc	Tofersen (Qalsody)	Qalsody (tofersen)^								
Neuromuscular Agents - Misc	Edaravone (Radicava)	Radicava (edaravone)				Y	Y			Y
Neuromuscular Agents - Misc	Antisense Oligonucleotide Therapy for Duchenne Muscular Dystrophy	Viltepso (viltolarsen)^								
Neuromuscular Agents - Misc	Antisense Oligonucleotide Therapy for Duchenne Muscular Dystrophy	Vyondys 53 (golodirsen)^								
Neuromuscular Agents - Misc	Efgartigimod Alfa-fcab (Vyvgart)	Vyvgart (efgartigimod alfa-fcab)	Y							
Ophthalmic Agents	Ocular Angiogenesis Inhibitor Agents	Beovu (brolucizumab-dbll)	Y							
Ophthalmic Agents	Ocular Angiogenesis Inhibitor Agents	Byooviz (ranibizumab-nuna)	Y	Y						
Ophthalmic Agents	Ocular Angiogenesis Inhibitor Agents	Cimerli (ranibizumab-eqrn)	Y	Y						
Ophthalmic Agents	Bimatoprost Intracameral Implant (Durysta)	Durysta (bimatoprost intracameral implant)	Y							
Ophthalmic Agents	Ocular Angiogenesis Inhibitor Agents	Eylea (aflibercept)	Y							

Therapeutic Category	Prior Authorization Policy Name	Drug Name	Step Therapy	Preferred	Quantity Limits	Site of Care	Pharmacy Benefit Coverage	Channel Mgmt	Medical Oncology Program	High Cost Therapy Review
Ophthalmic Agents	Ocular Angiogenesis Inhibitor Agents	Lucentis (ranibizumab)	Y							
Ophthalmic Agents	Ocular Angiogenesis Inhibitor Agents	Macugen (pegaptanib)	Y							
Ophthalmic Agents	Ocular Angiogenesis Inhibitor Agents	Susvimo (ranibizumab)	Y							
Ophthalmic Agents	Pegcetacoplan (Syfovre)	Syfovre (pegcetacoplan)								
Ophthalmic Agents	Ocular Angiogenesis Inhibitor Agents	Vabysmo (faricimab-svoa)	Y							
Respiratory Agents	Alpha 1-Antitrypsin Inhibitor Therapy	Aralast NP (alpha 1 proteinase inhibitor)				Y				
Respiratory Agents	Interleukin-5 Antagonists	Cinqair (reslizumab)				Y				
Respiratory Agents	Interleukin-5 Antagonists	Fasenra (benralizumab)				Y	Y	Y		
Respiratory Agents	Alpha 1-Antitrypsin Inhibitor Therapy	Glassia (alpha 1 proteinase inhibitor)				Y				
Respiratory Agents	Interleukin-5 Antagonists	Nucala (mepolizumab)	Y			Y	Y	Y		
Respiratory Agents	Alpha 1-Antitrypsin Inhibitor Therapy	Prolastin-C (alpha 1 proteinase inhibitor)				Y				
Respiratory Agents	Respiratory Syncytial Virus Prophylaxis	Synagis (palivizumab)								
Respiratory Agents	Tezepelumab-ekko (Tezspire)	Tezspire (tezepelumab-ekko)	Y			Y	Y			
Respiratory Agents	Omalizumab (Xolair)	Xolair (omalizumab)	Y			Y	Y	Y		
Respiratory Agents	Alpha 1-Antitrypsin Inhibitor Therapy	Zemaira (alpha 1 proteinase inhibitor)				Y				

Below are definitions of medical management strategies for specialty drugs:

Medical Necessity Review:

Standard drug-related medical policies are created and maintained by Blue Cross NC's clinical experts with the intent of reviewing medical necessity (MN) to promote appropriate use of products typically administered by a health care provider, in order to ensure use is effective and clinically appropriate according to generally accepted standards of medical practice. The MN review may include any or all aspects of prior authorization (PA), step therapy (ST) and/or quantity limitation (QL). All medications on the Medical Management Drug Guide require MN review unless otherwise indicated (e.g., drugs deemed for investigational use only).

* beside drug name indicates no additional medical necessity review required

^ beside drug name indicates investigational use only

Step Therapy (ST):

Medical drugs that require prerequisite medications be trialed or have clinical reasoning that the prerequisite cannot be used prior to approval. All step therapy requirements within our medical policies are through lowest cost alternatives that have demonstrated similar or superior clinical benefit and safety for the same indication. Step therapy criteria may only apply to certain indications, as outlined in each individual applicable drug-related medical

Preferred:

Preferred medical drugs are favored before use of another product within the same line of therapy or similar mechanism of action that has demonstrated similar or superior clinical benefit and safety for the same indication. Non-preferred medications will not be authorized or covered unless reviewed and approved by Blue Cross NC and the prior review involves addressing the use of other preferred medications. Preferred medical drugs may still require prior review for medical necessity; however, these drugs are favored before use of non-preferred medical drugs, as specified within each individual applicable drug-related medical policy.

Quantity Limitations (QL):

The Quantity Limitations (QL) indicator is used to note specific medical drugs that have a set maximum amount of units allowed on initial approval and require clinical criteria be met prior to approval of requests above the quantity limit. Quantity limitations are based on the standard dosing recommendations placed on products in the Prescribing Information from the Food and Drug Administration (FDA).

Site of Care (SOC):

The Place of Service for Medical Infusions medical policy outlines criteria for medical necessity and administration of certain injectable medications at a hospital inpatient or outpatient facility. The initial administration of the medications included in this program may be given at the physician's facility of choice. All subsequent administrations of the applicable medications will need to meet the program criteria.

Pharmacy Benefit Coverage:

Medical drugs where coverage may be available on both the medical benefit and the pharmacy benefit. This only applies to groups that also have pharmacy benefit coverage with Blue Cross NC.

Channel Management:

The Channel Management indicator is used to note that coverage of a drug should be first through an alternative benefit (e.g., Pharmacy) prior to the medical benefit. Additionally, channel management may also be required for coverage of certain identified gene and cellular therapies where distribution from a specialty pharmacy is required due to cost (e.g., distribution channel restriction).

Medical Oncology Program:

The Medical Oncology Program ensures outpatient medical oncology drugs are used according to evidence-based guidelines per compendia and Prescribing Information from the FDA. The program identifies care that is appropriate, safe, and affordable, in order to improve cancer care quality for eligible Blue Cross NC members. More specific than guidelines, this program identifies treatments based on clinical efficacy, favorable toxicity profiles, and cost. The Medical Oncology Program supports all regimens that meet the clinical review criteria under Blue Cross NC medical policies and clinical guidelines.

High Cost Therapy Review:

The High Cost Therapy Review program provides specialty-matched physician review of applicable medical drugs using evidence-based supported recommendations for identified high-cost, complex specialty drugs. This enhanced review process ensures appropriateness of therapy along with cost avoidance for select therapies for rare and complex disease states.

Note:

The Medical Management Drug Guide is not all-inclusive and does not reflect every medication that can be covered on the medical benefit. Certain medical drugs that have coverage available without medical necessity review may not be listed here. This Guide is regularly updated and is subject to change based on new approvals and market/industry changes. New-to-market products and variations of those products will not be added to the Medical Management Drug Guide until they have been endorsed by Blue Cross NC's P&T Committee.